1. Home
  2. AHG vs REPL Comparison

AHG vs REPL Comparison

Compare AHG & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHG

Akso Health Group ADS

SELL

Current Price

$1.27

Market Cap

1.1B

ML Signal

SELL

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$21.91

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AHG
REPL
Founded
2013
2015
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
AHG
REPL
Price
$1.27
$21.91
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $23.33
AVG Volume (30 Days)
7.2K
★ 3.2M
Earning Date
07-23-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$513.15
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$1.50
52 Week High
$2.50
$23.64

Technical Indicators

Market Signals
Indicator
AHG
REPL
Relative Strength Index (RSI) 56.28 72.51
Support Level $1.14 $7.11
Resistance Level $1.49 N/A
Average True Range (ATR) 0.11 1.65
MACD -0.01 0.58
Stochastic Oscillator 55.88 85.87

Price Performance

Historical Comparison
AHG
REPL

About AHG Akso Health Group ADS

Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: